Jihan Khan

[Jihan Khan @jkhanDRG]

What is in Store for the Hyperkalemia Market? | DRG Blog | DRG https://t.co/tngXzYln2V

[Jihan Khan @jkhanDRG]

HIF-PH Inhibitors: A New Hope for Renal Anemia? | DRG Blog | DRG https://t.co/0QUISRPMo3

[Kerri Brown @itskerribrown]

Oh! I co-authored a #hemophilia article in #Nature Reviews Drug Discovery 🤗 it published May 21. Click on the link to read my and @ggreen_DRG’s take on the hemophilia drug market: https://t.co/kKBuLGNzeC #DRG

[Jihan Khan @jkhanDRG]

ERA-EDTA 2018: Congress Highlights | DRG Blog | DRG https://t.co/VuCEU7dWHH

[Jihan Khan @jkhanDRG]

Oral Semaglutide: A PIONEERing new Treatment for Type 2 Diabetes? | DRG Blog, Drug Watch | DRG https://t.co/HtRieeD3KM

[Jihan Khan @jkhanDRG]

Will strategic ESA partnership by Amgen and Roche successfully defend against the imminent threat of Pfizer’s ESA... https://t.co/QdYj6BsEfp

[Gideon Heap @GideonHealth]

NOVO's new GLP-1, Ozempic, now approved in US, EU, and Japan $NVO https://t.co/NPrsrkuSVH

[Gideon Heap @GideonHealth]

US gives drug approval, EU declines. Interesting to see how this type of split decision plays out after #Brexit . https://t.co/DuuWeYL4O6

[David Rees @DavidRees_DRG]

What looks hot at the WCO-IOF-ESCEO this year? My guide to this year's osteoporosis conference #OsteoCongress
https://t.co/OgOZE8EMCO

[Jihan Khan @jkhanDRG]

Finally, Some Hope for AKI Treatment thanks to AM-Pharma's recAP | DRG Blog | DRG #STOPAKI #AKI #acutekidneyinjury #acuterenalfailue #ARF #AMpharma #recAP #alkalinephosphatase https://t.co/bAWyGaumVw

[Clarivate Epidemiology @DRG_Epi]

#DRG new global epidemiology analysis finds that 77% of all prevalent cases of #type2diabetes worldwide are in lower-income countries https://t.co/r92nrjx1mO #T2D #diabetes #adultdiabetes @DRGinsights

[Gideon Heap @GideonHealth]

My take on Orexigen and the troubled weight loss drug, Contrave. $OREX $VVUS $ARNA #obesity @DRGinsights https://t.co/g5F2DW7tDU

[Jihan Khan @jkhanDRG]

Hyperkalemia Market Could Hit Over $2 Billion in Sales https://t.co/2cYKzuzjKM #WorldKidneyDay

[Jihan Khan @jkhanDRG]

Ferric Citrate (Auryxia) Approved for Anemia in CKD Patients – What are Nephrologists Thinking?:
https://t.co/OMEp6BwTeP #WorldKidneyDay

[Jihan Khan @jkhanDRG]

HIF-PH inhibitors expected to shake up the renal anemia market: https://t.co/BQqc5vOsAI #WorldKidneyDay

[Andrew Frost @AFrost_DRG]

"HCV is beautiful in its simplicity; NASH is fascinating in its complexity". Very nice talk from @Novartis at the afternoon session of the #NASHCONGRESS on the potential for combination therapies in NASH. @DRGinsights #NASH

[Andrew Frost @AFrost_DRG]

Another fascinating morning session at the #NASHCONGRESS, with 3 talks on the future of non-invasive biomarkers in NASH. Some really nice visual examples from @LiverMultiScan. #NASH

[Gideon Heap @GideonHealth]

"With four emerging therapies in Phase III trials for NASH, we are at an exciting point in the disease’s history; the first approved therapies are within our grasp." @AFrost_DRG blog on NASH congress $GILD $GNFT $ICPT https://t.co/dHVYQEp9WS

[Gideon Heap @GideonHealth]

Unlike $NVO ‘s excluded GLP-1 Victoza, the new once-weekly Ozempic will be included on Express Scripts tier 3. Crucial to compete with the preferred status GLP-1s from $LLY $AZN (Trulicity, Byetta, Bydureon). Expect Ozempic to take a big bite out of Trulicity’s growth. #diabetes